+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Healthcare Contract Development & Manufacturing Organization Market by Service Offering, Molecule Type, Dosage Form, Application, Therapeutic Area, End User - Global Forecast 2026-2032- Product Image
Healthcare Contract Development & Manufacturing Organization Market by Service Offering, Molecule Type, Dosage Form, Application, Therapeutic Area, End User - Global Forecast 2026-2032- Product Image
Sale

Healthcare Contract Development & Manufacturing Organization Market by Service Offering, Molecule Type, Dosage Form, Application, Therapeutic Area, End User - Global Forecast 2026-2032

  • Report

  • 194 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5456956
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Healthcare Contract Development & Manufacturing Organization Market is projected to reach USD 391.77 Billion in 2026. It is expected to continue growing at a CAGR of 9.23%, reaching USD 668.80 Billion by 2032.

Healthcare contract development and manufacturing organizations are becoming strategic infrastructure for pharmaceutical, biotechnology, cell and gene therapy, vaccine, and medical device companies. The sector is supported by measurable demand drivers, including patent expirations, biologics growth, complex sterile manufacturing needs, supply chain diversification, and continued regulatory emphasis on quality-by-design.

CDMOs now compete on more than capacity. Sponsors increasingly evaluate partners by FDA, EMA, MHRA, PMDA, and WHO-aligned compliance records; technology transfer discipline; data integrity; containment capability; cold-chain readiness; and the ability to scale from clinical batches to commercial supply without compromising current good manufacturing practice standards.

Transformative Shifts in the CDMO Landscape

The healthcare CDMO landscape is shifting from transactional outsourcing to integrated development, manufacturing, packaging, and lifecycle management partnerships. Demand is rising for sterile injectables, high-potency active pharmaceutical ingredients, biologics, biosimilars, mRNA platforms, and advanced therapy medicinal products, where technical barriers and regulatory scrutiny favor experienced operators.

At the same time, sponsors are redesigning supply networks after pandemic-era disruptions, inflationary pressure, energy cost volatility, and geopolitical risk exposure. Dual sourcing, regionalized manufacturing, validated backup capacity, and stronger supplier qualification have become board-level priorities, especially for essential medicines, critical APIs, and temperature-sensitive biologics.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is reshaping CDMO value creation across formulation screening, process development, predictive maintenance, deviation analysis, visual inspection, demand forecasting, and regulatory documentation. The strongest use cases are emerging where AI is paired with validated data pipelines, electronic batch records, laboratory information management systems, manufacturing execution systems, and quality management systems.

Regulators have not lowered expectations for control, traceability, or human accountability. FDA, EMA, and ICH quality frameworks continue to require data integrity, explainability, risk management, and documented validation. For CDMOs, AI advantage depends on governed implementation, model monitoring, cybersecurity controls, and audit-ready documentation rather than experimental automation alone.

Key Regional Insights

Asia-Pacific is expanding as a development and manufacturing hub, led by China, India, Japan, South Korea, Singapore, and Australia, with strengths in APIs, generics, biologics, biosimilars, vaccines, and clinical trial supply. The region benefits from established active ingredient ecosystems, growing domestic healthcare demand, government-backed life sciences investment, and rising adoption of international GMP standards. North America remains a premium CDMO region because of FDA proximity, advanced biologics infrastructure, venture-backed biotechnology demand, strong intellectual property protection, and deep capabilities in sterile fill-finish, cell therapy, gene therapy, and complex drug-device combinations.

Europe benefits from EMA coordination, mature GMP systems, high-value sterile and biologics manufacturing, and strong specialty pharmaceutical clusters across Western and Central Europe. Latin America is gaining relevance through Brazil and Mexico, where regulated pharmaceutical production, public health procurement, and nearshoring dynamics support regional CDMO activity. The Middle East is investing in localization through Saudi Arabia and the UAE, with national strategies focused on medicine security, technology transfer, and domestic pharmaceutical production. Africa is at an earlier stage, supported by vaccine manufacturing initiatives, the African Medicines Agency, and AfCFTA-enabled regional integration designed to improve access, harmonize regulation, and reduce dependence on imported essential medicines.

Key Economic & Strategic Group Insights

ASEAN is strengthening its role in pharmaceutical packaging, clinical supply, and regional manufacturing, supported by Singapore's biomanufacturing base and growing healthcare demand across Indonesia, Thailand, Vietnam, Malaysia, and the Philippines. The group is also benefiting from regulatory cooperation efforts, expanding hospital networks, and demand for affordable generics and specialty medicines. The GCC is prioritizing medicine security and local production, particularly in Saudi Arabia and the UAE, where industrial policy, healthcare modernization, and procurement localization are encouraging pharmaceutical manufacturing partnerships.

The European Union remains a leading quality and regulatory reference market, supported by harmonized medicinal product oversight, advanced pharmacovigilance systems, and high GMP expectations. BRICS countries offer scale, API depth, vaccine experience, and fast-expanding healthcare consumption, with China and India particularly important to global pharmaceutical supply chains. G7 markets continue to dominate high-value innovation outsourcing because of advanced R&D ecosystems, mature regulators, and demand for complex biologics, sterile products, and advanced therapies. NATO economies add resilience considerations, as defense preparedness, secure supply chains, stockpiling policies, and essential medicine availability increasingly intersect with healthcare manufacturing strategy.

Key Country Insights

The United States leads demand for advanced CDMO services through biotechnology innovation, FDA-regulated commercialization, strong capital markets, and significant demand for biologics, sterile injectables, cell therapies, gene therapies, and complex generics. Canada supports biologics, vaccines, radiopharmaceuticals, and clinical-stage development through public investment in biomanufacturing resilience and a research-intensive life sciences base, while Mexico benefits from nearshoring, competitive manufacturing economics, and proximity to U.S. supply chains. Brazil anchors Latin American pharmaceutical manufacturing through ANVISA-regulated scale, domestic generic demand, vaccine capabilities, and a large public healthcare system.

The United Kingdom, Germany, France, Italy, and Spain remain important European CDMO markets, supported by MHRA and EMA-aligned quality expectations, skilled scientific workforces, and established pharmaceutical manufacturing clusters. Germany and France are especially strong in pharmaceuticals, specialty manufacturing, injectables, and bioprocessing, while Italy and Spain provide mature contract manufacturing, packaging, and finished-dose capabilities. Russia maintains domestic pharmaceutical production priorities driven by import substitution and medicine security policies, though sanctions and supply restrictions influence technology access and cross-border partnerships. China and India provide major API, generics, biosimilars, and biologics capacity, with China emphasizing integrated innovation and India retaining global strength in cost-efficient development and regulated generics. Japan emphasizes quality, specialty innovation, and PMDA-aligned compliance; South Korea is a global biologics manufacturing leader with strong biosimilar and bioprocessing capabilities; and Australia supports clinical trials, early development, vaccines, and Asia-Pacific regulatory bridging through strong healthcare infrastructure and internationally recognized research standards.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize resilient, quality-led growth. Recommended actions include qualifying dual suppliers for critical materials, investing in sterile and biologics capacity, strengthening technology transfer governance, and aligning operations with ICH Q9(R1), Q10, Q12, Q13, and emerging AI-related regulatory expectations.

CDMOs should also build differentiated capabilities in high-potency manufacturing, aseptic processing, single-use bioprocessing, advanced analytics, serialization, cold-chain logistics, and sustainability reporting. Sponsors should select partners through risk-based scorecards that evaluate inspection history, data integrity, digital maturity, scalability, financial stability, cybersecurity posture, environmental controls, and demonstrated performance in comparable products.

Research Methodology

This executive summary is grounded in secondary research from publicly available regulatory, policy, scientific, and industry sources, including FDA, EMA, MHRA, WHO, ICH, OECD, national health agencies, public health procurement documents, inspection guidance, scientific publications, company filings, investor disclosures, and peer-reviewed literature. The analysis emphasizes verifiable structural indicators such as manufacturing capability, regulatory frameworks, inspection expectations, supply chain trends, therapeutic modality requirements, and documented policy priorities.

Insights are synthesized through a market-mapping approach that compares regions, strategic groups, and countries across demand drivers, compliance maturity, outsourcing intensity, technology adoption, manufacturing specialization, and supply resilience. The methodology avoids unsupported market-size, market-share, or forecasting claims and uses only evidence-based directional insights supported by identifiable public sources.

Conclusion

The healthcare CDMO market is entering a more strategic phase defined by technical complexity, quality expectations, regional diversification, and digital transformation. Sponsors are relying on CDMOs not only to reduce fixed manufacturing investment but also to access specialized expertise, accelerate development timelines, support regulatory readiness, and protect supply continuity.

The strongest CDMO performers will combine regulatory credibility, flexible capacity, AI-enabled process intelligence, robust quality systems, skilled technical teams, and global network resilience. As biologics, sterile products, advanced therapies, vaccines, high-potency compounds, and complex generics expand, trusted CDMO partnerships will remain essential to competitive healthcare manufacturing.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Healthcare Contract Development & Manufacturing Organization Market, by Service Offering
7.1. Contract Development Services
7.1.1. Clinical Development
7.1.1.1. Clinical Trials Support
7.1.1.2. Regulatory Support
7.1.2. Preclinical Development
7.1.2.1. In Vitro & In Vivo Studies
7.1.2.2. Toxicology Studies
7.1.3. Process Development
7.2. Contract Manufacturing Services
7.2.1. API Manufacturing
7.2.2. Finished Dosage Form Manufacturing (FDF)
7.2.3. Medical Device Manufacturing
7.2.4. Packaging & Labeling
8. Healthcare Contract Development & Manufacturing Organization Market, by Molecule Type
8.1. Large Molecules
8.1.1. Monoclonal Antibodies
8.1.2. Recombinant Proteins
8.1.3. Vaccines
8.2. Small Molecules
9. Healthcare Contract Development & Manufacturing Organization Market, by Dosage Form
9.1. Liquid Dosage Forms
9.2. Semi-Solid Dosage Forms
9.3. Solid Dosage Forms
10. Healthcare Contract Development & Manufacturing Organization Market, by Application
10.1. Generic Drugs
10.2. Medical Devices
10.3. Patented Drugs
11. Healthcare Contract Development & Manufacturing Organization Market, by Therapeutic Area
11.1. Cardiology
11.2. Immunology
11.3. Infectious Disease
11.4. Metabolic Disorders
11.5. Neurology
11.6. Oncology
12. Healthcare Contract Development & Manufacturing Organization Market, by End User
12.1. Academic & Research Institutions
12.2. Biotechnology Companies
12.3. Generic Drug Manufacturers
12.4. Medical Device Companies
12.5. Pharmaceutical Companies
12.5.1. Big Pharmaceutical Companies
12.5.2. Small & Medium-sized Pharmaceutical Companies
13. Asia-Pacific Healthcare Contract Development & Manufacturing Organization Market
14. North America Healthcare Contract Development & Manufacturing Organization Market
15. Latin America Healthcare Contract Development & Manufacturing Organization Market
16. Europe Healthcare Contract Development & Manufacturing Organization Market
17. Middle East Healthcare Contract Development & Manufacturing Organization Market
18. Africa Healthcare Contract Development & Manufacturing Organization Market
19. ASEAN Healthcare Contract Development & Manufacturing Organization Market
20. GCC Healthcare Contract Development & Manufacturing Organization Market
21. European Union Healthcare Contract Development & Manufacturing Organization Market
22. BRICS Healthcare Contract Development & Manufacturing Organization Market
23. G7 Healthcare Contract Development & Manufacturing Organization Market
24. NATO Healthcare Contract Development & Manufacturing Organization Market
25. United States Healthcare Contract Development & Manufacturing Organization Market
26. Germany Healthcare Contract Development & Manufacturing Organization Market
27. China Healthcare Contract Development & Manufacturing Organization Market
28. United Kingdom Healthcare Contract Development & Manufacturing Organization Market
29. India Healthcare Contract Development & Manufacturing Organization Market
30. Japan Healthcare Contract Development & Manufacturing Organization Market
31. Russia Healthcare Contract Development & Manufacturing Organization Market
32. Brazil Healthcare Contract Development & Manufacturing Organization Market
33. Canada Healthcare Contract Development & Manufacturing Organization Market
34. Italy Healthcare Contract Development & Manufacturing Organization Market
35. Mexico Healthcare Contract Development & Manufacturing Organization Market
36. France Healthcare Contract Development & Manufacturing Organization Market
37. Spain Healthcare Contract Development & Manufacturing Organization Market
38. Australia Healthcare Contract Development & Manufacturing Organization Market
39. South Korea Healthcare Contract Development & Manufacturing Organization Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. Baxter International, Inc.
41.2. Boehringer Ingelheim International GmbH
41.3. Cambrex Corporation
41.4. Catalent Inc.
41.5. Charles River Laboratories International, Inc.
41.6. Corden Pharma International GmbH
41.7. Curia Global, Inc.
41.8. Eurofins Scientific SE
41.9. EVER company group
41.10. Evonik Industries AG
41.11. FUJIFILM Diosynth Biotechnologies
41.12. Jabil, Inc.
41.13. Lonza Group AG
41.14. MedPharm Ltd.
41.15. Merck KGaA
41.16. NextPharma GmbH
41.17. Piramal Group
41.18. Porton Pharma Solutions Ltd
41.19. Recipharm AB
41.20. Samsung Biologics
41.21. Sanmina Corporation
41.22. Siegfried Holding AG
41.23. Siegfried-Group
41.24. Thermo Fisher Scientific, Inc.
41.25. WuXi AppTec
List of Figures
FIGURE 1. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2025 VS 2032 (%)
FIGURE 15. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 19. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 23. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 25. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. UNITED STATES HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. GERMANY HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. CHINA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. UNITED KINGDOM HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. INDIA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. JAPAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. RUSSIA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. BRAZIL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. CANADA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. ITALY HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. MEXICO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. FRANCE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SPAIN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. AUSTRALIA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SOUTH KOREA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CONTRACT DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CONTRACT DEVELOPMENT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CONTRACT DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CLINICAL DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CLINICAL DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CLINICAL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CLINICAL TRIALS SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CLINICAL TRIALS SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CLINICAL TRIALS SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL REGULATORY SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL REGULATORY SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL REGULATORY SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL PRECLINICAL DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL PRECLINICAL DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL PRECLINICAL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL IN VITRO & IN VIVO STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL IN VITRO & IN VIVO STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL IN VITRO & IN VIVO STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL TOXICOLOGY STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL TOXICOLOGY STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL TOXICOLOGY STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CONTRACT MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CONTRACT MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CONTRACT MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL API MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL API MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL API MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL FINISHED DOSAGE FORM MANUFACTURING (FDF) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL FINISHED DOSAGE FORM MANUFACTURING (FDF) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL FINISHED DOSAGE FORM MANUFACTURING (FDF) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MEDICAL DEVICE MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MEDICAL DEVICE MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL MEDICAL DEVICE MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL PACKAGING & LABELING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL PACKAGING & LABELING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL PACKAGING & LABELING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL LARGE MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL LARGE MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL LARGE MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL LIQUID DOSAGE FORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL LIQUID DOSAGE FORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL LIQUID DOSAGE FORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL SEMI-SOLID DOSAGE FORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL SEMI-SOLID DOSAGE FORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL SEMI-SOLID DOSAGE FORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL SOLID DOSAGE FORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL SOLID DOSAGE FORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL SOLID DOSAGE FORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL GENERIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL MEDICAL DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL MEDICAL DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL MEDICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL PATENTED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL PATENTED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL PATENTED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL IMMUNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL IMMUNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL IMMUNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL GENERIC DRUG MANUFACTURERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL GENERIC DRUG MANUFACTURERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL GENERIC DRUG MANUFACTURERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL MEDICAL DEVICE COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL MEDICAL DEVICE COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL MEDICAL DEVICE COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL BIG PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL BIG PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL BIG PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
TABLE 140. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
TABLE 141. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 142. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 143. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
TABLE 144. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 149. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 151. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 152. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
TABLE 153. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
TABLE 154. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 155. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 156. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
TABLE 157. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 158. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
TABLE 159. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 160. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 161. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 162. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 163. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 164. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 165. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
TABLE 166. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
TABLE 167. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 168. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 169. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
TABLE 170. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 171. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
TABLE 172. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 173. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 174. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 175. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 181. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 182. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
TABLE 183. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 184. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
TABLE 185. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 186. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 187. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 188. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 189. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 190. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 191. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
TABLE 192. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
TABLE 193. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 194. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 195. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
TABLE 196. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 197. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
TABLE 198. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 199. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 200. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 201. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 202. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 203. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 204. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
TABLE 205. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
TABLE 206. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 207. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 208. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
TABLE 209. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 210. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
TABLE 211. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 212. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 213. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 214. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 215. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 216. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 217. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
TABLE 218. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
TABLE 219. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 220. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 221. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
TABLE 222. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 223. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
TABLE 224. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 225. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 226. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 227. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 228. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 242. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 243. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
TABLE 244. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
TABLE 245. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 246. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 247. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
TABLE 248. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 249. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
TABLE 250. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 251. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 252. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 253. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 254. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 255. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 256. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
TABLE 257. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
TABLE 258. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 259. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 260. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
TABLE 261. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 262. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
TABLE 263. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 264. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 265. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 266. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 267. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 268. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 269. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
TABLE 270. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
TABLE 271. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 272. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 273. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
TABLE 274. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 275. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
TABLE 276. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 277. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 278. NATO HEALTHCARE CONTRACT DEVELOPMENT &

Companies Mentioned

The companies featured in this Healthcare Contract Development & Manufacturing Organization market report include:
  • Baxter International, Inc.
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent Inc.
  • Charles River Laboratories International, Inc.
  • Corden Pharma International GmbH
  • Curia Global, Inc.
  • Eurofins Scientific SE
  • EVER company group
  • Evonik Industries AG
  • FUJIFILM Diosynth Biotechnologies
  • Jabil, Inc.
  • Lonza Group AG
  • MedPharm Ltd.
  • Merck KGaA
  • NextPharma GmbH
  • Piramal Group
  • Porton Pharma Solutions Ltd
  • Recipharm AB
  • Samsung Biologics
  • Sanmina Corporation
  • Siegfried Holding AG
  • Siegfried-Group
  • Thermo Fisher Scientific, Inc.
  • WuXi AppTec

Table Information

Report AttributeDetails
No. of Pages194
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 391.77 Billion
Forecasted Market Value ( USD ) by 2032 $ 668.8 Billion
Compound Annual Growth Rate9.2%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Biologics Contract Development & Manufacturing Organization Market - Global Forecast 2026-2032 - Product Image

Biologics Contract Development & Manufacturing Organization Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Healthcare Contract Development and Manufacturing Organization - Global Strategic Business Report - Product Image

Healthcare Contract Development and Manufacturing Organization - Global Strategic Business Report

  • Report
  • 117 Pages
  • Global
From
Healthcare Contract Development and Manufacturing Organization Market Size, Share & Trends Analysis Report by Type, Product, Service, Workflow, Therapeutic Area, End-use, and Region with Growth Forecasts, 2025-2033 - Product Image

Healthcare Contract Development and Manufacturing Organization Market Size, Share & Trends Analysis Report by Type, Product, Service, Workflow, Therapeutic Area, End-use, and Region with Growth Forecasts, 2025-2033

  • Report
  • 120 Pages
  • Global
From
Antibody Contract Development and Manufacturing Organization - Global Strategic Business Report - Product Image

Antibody Contract Development and Manufacturing Organization - Global Strategic Business Report

  • Report
  • 276 Pages
  • Global
From
Pharmaceutical Contract Development and Manufacturing Organization Market Size, Share & Trends Analysis Report by Type (Small Molecule, Large Molecule), Product (API, Drug), Services, Workflow, Therapeutic Area, End Use, and Region with Growth Forecasts, 2025-2033 - Product Image

Pharmaceutical Contract Development and Manufacturing Organization Market Size, Share & Trends Analysis Report by Type (Small Molecule, Large Molecule), Product (API, Drug), Services, Workflow, Therapeutic Area, End Use, and Region with Growth Forecasts, 2025-2033

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.